Project Grant R21HL181317
Award Date 8/15/25
Completion Date 7/31/27
Dollars Obligated $429K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Michigan, USA
Similar Awards
- This Cooperative Agreement award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), will develop new pulmonary magnetic resonance imaging (MRI) methods on a novel 0.55 Tesla scanner. The $659,644 project, running from September 2025 to June 2029, will focus on improving the spatial resolution and image contrast of structural lung proton MRI, as well as developing methodology for hyperpolarized xenon imaging at this...
- This federal Project Grant award of $747,281 from the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) supports the development of a real-time, non-invasive technique to characterize the mechanical properties of blood clots (thrombi) as they age. The project aims to utilize ultrasound-responsive nanodroplets that can transition into microbubbles when exposed to focused ultrasound, a process known as acoustic droplet vaporization (ADV). By leveraging ADV, the...
- This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) aims to develop a comprehensive PET attenuation correction scheme for cardiac PET/MR imaging. The $739,466 project, awarded on August 1, 2025 and scheduled for completion by May 31, 2030, will utilize hardware, image reconstruction, and deep learning algorithms to directly measure and correct for PET attenuation based on physics principles. The goals are to fabricate a...
- The Project Grant award of $759,658 from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) supports research at The General Hospital Corporation (doing business as Massachusetts General Hospital) to develop and validate a mechanomicroscopy imaging platform for the transbronchial assessment of pulmonary artery pressure and arterial smooth muscle thickening in patients with pulmonary hypertension due to lung disease. The key products and services to be...
- The Project Grant award from the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) provides $268,500 to Brigham & Women's Hospital Inc. to develop and validate a quantitative marker of pulmonary microvascular injury and explore the correlation between microvascular volume loss and the longitudinal progression of chronic obstructive pulmonary disease (COPD) and emphysema in smokers. The research leverages an AI-based algorithm to assess vascular...
- This Project Grant award from the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) provides $306,530.00 to Spinhance LLC to build, qualify, and evaluate the clinical feasibility of a novel cardiopulmonary imaging device. The device is designed for continuous administration of the magnetic resonance imaging (MRI) contrast agent hyperpolarized xenon-129 (HPX), which was recently approved by the FDA. The project aims to develop an MRI-compatible, piston-based...
- This Project Grant award of $108,003.00, provided by the National Heart Lung and Blood Institute under CFDA Program 93.837 Cardiovascular Diseases Research, supports a study on "Early Changes of T2* Measures in Lung Tissues Using Deltate-UTE MRI on Healthy and COPD Patients" at the University of California, San Diego (UCSD). The goal is to develop an advanced ultrashort echo-time (UTE) magnetic resonance imaging (MRI) technique, called TE-UTE, to accurately map T2* values in lung...
- This federal Project Grant award of $461,115.00, provided by the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research), will support research to assess the use of hyperpolarized 129Xe MRI as a non-invasive biomarker for evaluating pulmonary vascular function in asthma patients. The research aims to address the unmet need for a sensitive technique to measure regional vascular function within the lungs, which may contribute to asthma presentation and severity....
- The Regents of the University of Michigan were awarded a $207,342 Project Grant from the National Heart Lung and Blood Institute's Cardiovascular Diseases Research program (CFDA 93.837) on September 12, 2025. The goal of this 5-year program is to enhance research training and career development opportunities for Emergency Medicine (EM) resident investigators at the University of Michigan. The program will recruit and train 2 outstanding EM resident trainees annually, providing them with 12...
- This Project Grant award from the National Heart Lung and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $1,061,189 to the Regents of the University of Michigan to conduct research on immune crosstalk in lung injury and fibrosis. The key objectives are to study epithelial cell regulation of fibrosis and its interaction with myeloid cells, uncover mechanisms for impaired innate immunity against gram-positive infections in fibrosis, test delivery of targeted therapeutics...